Fetal therapies in congenital diaphragmatic hernia: a review of possibilities and practical challenges
Seminars in Fetal and Neonatal Medicine · 2025
DOI: 10.1016/j.siny.2025.101656 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Fetal and Neonatal Medicine, 2025. Verfasst von Adriana Dekirmendjian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Canada; Division of General and Thoracic Surgery, The Hospital fo…. Hauptthemen laut MEDLINE: Hernias, Diaphragmatic, Congenital, Fetal Therapies, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 217 Literaturangaben. Gefördert von: Washington University in St Louis, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Congenital diaphragmatic hernia (CDH) is characterized by pulmonary hypoplasia. CDH lungs exhibit an inflammatory signature with impaired growth, maturation, and vascularization, which postnatally result in altered gas exchange and pulmonary hypertension. These pulmonary abnormalities are drivers of poor survival and long-term morbidity. Improving lung development before birth remains a key strategy to enhance outcomes, and several antenatal therapies have emerged to address this need. These include surgical procedures, pharmacologic agents, and regenerative approaches. Fetal Endoluminal Tracheal Occlusion has shown the most robust evidence, improving survival in selected CDH cases. However, concerns about its generalizability, complications, and its limited effect on overall lung development have underscored the need for complementary or alternative strategies. A wide range of pharmacologic agents, some of which are in clinical use while others remain experimental, has been studied in experimental CDH models, such as corticosteroids, anti-inflammatory drugs and vasoactive medications. In parallel, regenerative medicine strategies via the antenatal administration of stem cells or their derivatives (extracellular vesicles) offer promise through multi-targeted mechanisms that address several aspects of pulmonary hypoplasia. Encouraging preclinical results provide a promising basis for advancing these regenerative therapies toward clinical application, with ongoing investigations focused on establishing their safety, efficacy, and feasibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Canada; Division of General and Thoracic Surgery, The Hospital for Sick Children, Toronto, Canada.
- Division of General and Thoracic Surgery, The Hospital for Sick Children, Toronto, Canada; Developmental and Stem Cell Biology Program, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toro…
Förderung
- Washington University in St Louis
- Canadian Institutes of Health Research
Zitieren
APA
Dekirmendjian, A., Doktor, F., Antounians, L., & Zani, A. (2025). Fetal therapies in congenital diaphragmatic hernia: a review of possibilities and practical challenges. Seminars in Fetal and Neonatal Medicine. https://doi.org/10.1016/j.siny.2025.101656
Vancouver
Dekirmendjian A, Doktor F, Antounians L, Zani A. Fetal therapies in congenital diaphragmatic hernia: a review of possibilities and practical challenges. Seminars in Fetal and Neonatal Medicine. 2025. doi:10.1016/j.siny.2025.101656
BibTeX
@article{Dekirmendjian2025,
author = {Dekirmendjian, Adriana and Doktor, Fabian and Antounians, Lina and Zani, Augusto},
title = {Fetal therapies in congenital diaphragmatic hernia: a review of possibilities and practical challenges},
journal = {Seminars in Fetal and Neonatal Medicine},
year = {2025},
doi = {10.1016/j.siny.2025.101656}
}
EUVIMED